During the last session, Gossamer Bio Inc (NASDAQ:GOSS)’s traded shares were 0.75 million, with the beta value of the company hitting 1.95. At the end of the trading day, the stock’s price was $0.96, reflecting an intraday loss of -1.90% or -$0.02. The 52-week high for the GOSS share is $1.60, that puts it down -66.67 from that peak though still a striking 53.12% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $218.31M, and the average intraday trading volume over the past 10 days was 0.98 million shares, and the average trade volume was 1.07 million shares over the past three months.

Gossamer Bio Inc (GOSS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.60. GOSS has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.

Gossamer Bio Inc (NASDAQ:GOSS) trade information

Gossamer Bio Inc (GOSS) registered a -1.90% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.90% in intraday trading to $0.96, hitting a weekly high. The stock’s 5-day price performance is -9.81%, and it has moved by 9.66% in 30 days. Based on these gigs, the overall price performance for the year is 44.94%. The short interest in Gossamer Bio Inc (NASDAQ:GOSS) is 7.75 million shares and it means that shorts have 8.59 day(s) to cover.

The consensus price target of analysts on Wall Street is $4, which implies an increase of 76.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, GOSS is trading at a discount of -420.83% off the target high and -108.33% off the low.

Gossamer Bio Inc (GOSS) estimates and forecasts

Statistics show that Gossamer Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Gossamer Bio Inc (GOSS) shares have gone up 7.80% during the last six months, with a year-to-date growth rate more than the industry average at 72.03% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 28.60% this quarter and then jump 28.60% in the quarter after that.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.7M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 7.71M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.99%. While earnings are projected to return 77.55% in 2024, the next five years will return 5.20% per annum.

GOSS Dividends

Gossamer Bio Inc is due to release its next quarterly earnings on 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders

Gossamer Bio Inc insiders own 2.95% of total outstanding shares while institutional holders control 81.13%, with the float percentage being 83.59%. NEA MANAGEMENT COMPANY, LLC is the largest shareholder of the company, while 104.0 institutions own stock in it. As of 2024-06-30, the company held over 18.09 million shares (or 8.0152% of all shares), a total value of $16.3 million in shares.

The next largest institutional holding, with 13.31 million shares, is of ARTAL GROUP S.A.’s that is approximately 5.8958% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.99 million.